Literature DB >> 23927644

Intrahepatic cholestasis in common chronic liver diseases.

Christoph Jüngst1, Thomas Berg, Jun Cheng, Richard M Green, Jidong Jia, Andrew L Mason, Frank Lammert.   

Abstract

BACKGROUND AND
OBJECTIVE: Cholestasis represents the consequence of impaired bile formation and decrease in bile flow, generally classified as extra- and intrahepatic. Cholestasis is the pivotal hallmark of the so-called primary cholestatic liver diseases but may also emerge in other forms of chronic liver injury. The aim now was to summarise the current state of knowledge on intrahepatic cholestasis related to chronic liver diseases.
METHODS: For this overview on intrahepatic cholestasis in chronic liver disorders other than the 'classic' cholestatic liver diseases, selected references were retrieved by literature search in MEDLINE and textbooks were reviewed. All articles were selected that discussed pathophysiological and clinical aspects of intrahepatic cholestasis in the context of alcoholic liver disease, nonalcoholic fatty liver disease, chronic hepatitis B and C virus infections as well as drug-induced and granulomatous liver diseases. Titles referring to primary biliary cirrhosis and sclerosing cholangitis were excluded. RESULTS AND
CONCLUSIONS: Dependent on the aetiology, intrahepatic cholestasis is present at variable frequencies and in different disease stages in chronic liver diseases. Cholestasis secondary to chronic liver injury may denote a severe disease course and development of end-stage liver disease or specific disease variants. These findings indicate that 'secondary intrahepatic cholestasis' (SIC) can occur in the natural course of chronic liver diseases other than the primary cholestatic diseases, in particular in the setting of advanced disease progression.
© 2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Alcoholic liver disease; bile; drug-induced cholestasis; fatty liver disease; viral hepatitis

Mesh:

Year:  2013        PMID: 23927644     DOI: 10.1111/eci.12128

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  17 in total

Review 1.  Pharmacotherapy of acute alcoholic hepatitis in clinical practice.

Authors:  Ludovico Abenavoli; Natasa Milic; Samir Rouabhia; Giovanni Addolorato
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 2.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

3.  Protective effect of bicyclol against bile duct ligation-induced hepatic fibrosis in rats.

Authors:  Yong-Zhan Zhen; Na-Ren Li; Hong-Wei He; Shuang-Shuang Zhao; Guang-Ling Zhang; Xiao-Fang Hao; Rong-Guang Shao
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

4.  Gut microbiome in liver pathophysiology and cholestatic liver disease.

Authors:  Shengmin Yan; Xiao-Ming Yin
Journal:  Liver Res       Date:  2021-08-08

5.  Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center.

Authors:  Rucha M Shah; Sarah Sheikh; Jimmy Shah; Elaina Vivian; Alejandro Mejia; Islam Shahin; Parvez S Mantry
Journal:  J Gastrointest Oncol       Date:  2021-08

Review 6.  Predictive value of serum bile acids as metabolite biomarkers for liver cirrhosis: a systematic review and meta-analysis.

Authors:  Xu Han; Juan Wang; Hao Gu; Hongtao Guo; Yili Cai; Xing Liao; Miao Jiang
Journal:  Metabolomics       Date:  2022-06-27       Impact factor: 4.747

Review 7.  Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer.

Authors:  Se-Young Park; Byeong-Oh Hwang; Mihwa Lim; Seung-Ho Ok; Sun-Kyoung Lee; Kyung-Soo Chun; Kwang-Kyun Park; Yinling Hu; Won-Yoon Chung; Na-Young Song
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

8.  Intestinal Microbiome-Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice.

Authors:  Anna Isaacs-Ten; Marta Echeandia; Mar Moreno-Gonzalez; Arlaine Brion; Andrew Goldson; Mark Philo; Angela M Patterson; Aimee Parker; Mikel Galduroz; David Baker; Simon M Rushbrook; Falk Hildebrand; Naiara Beraza
Journal:  Hepatology       Date:  2020-12       Impact factor: 17.298

9.  Anti-fibrotic effect of Holothuria arenicola extract against bile duct ligation in rats.

Authors:  Sohair R Fahmy
Journal:  BMC Complement Altern Med       Date:  2015-02-05       Impact factor: 3.659

10.  Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies.

Authors:  Federica Pulvirenti; Ilaria Pentassuglio; Cinzia Milito; Michele Valente; Adriano De Santis; Valentina Conti; Giulia d'Amati; Oliviero Riggio; Isabella Quinti
Journal:  J Immunol Res       Date:  2014-03-31       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.